2016

My videos
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group

Randomized Phase III Trial of Atezolizumab + Bevacizumab ...
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group at the 2018 ASCO.
189 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Microbiome Effects of Antibodies Can Linger for Up to 60 ...
136 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Using Microbiome Transplantation or FMT for RCC They sho...
150 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Systemic Therapy in Metastatic Renal Cell Carcinoma Antib...
196 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Subgroup analyses of METEOR
Subgroup analyses of METEOR
378 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
CheckMate 025 phase III trial
CheckMate 025 phase III trial
429 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Immunotherapy in non muscle invasive bladder cancer #GU16
Immunotherapy in non muscle invasive bladder cancer #GU16
580 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
How soon should we expect approval of immunotherapy in urothelial cancer #GU16
How soon should we expect approval of immunotherapy in u...
405 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Future role of immunotherapy and checkpoint inhibitors in urothelial cancer #GU16
Future role of immunotherapy and checkpoint inhibitors in...
609 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Atezolizumab shows very significant activity in advanced urothelial cancer #GU16
Atezolizumab shows very significant activity in advanced ...
473 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
Discontinuing VEGF-TT for progression versus toxicity imp...
328 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Genomics in urothelial carcinomas may play much bigger role in the future #GU16
Genomics in urothelial carcinomas may play much bigger ro...
401 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Inhibiting autophagy in bladder cancer #GU16
Inhibiting autophagy in bladder cancer #GU16
255 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Clinical and pathological factors that can influence outcomes in upper tract urothelial cancer #GU16
Clinical and pathological factors that can influence outc...
245 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Does treatment for prior cancer develop secondary bladder cancer #gu16
Does treatment for prior cancer develop secondary bladder...
401 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer
Annual Meeting GU 2016 Role of neoadjuvant chemotherapy a...
810 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Immune checkpoint inhibitors in combination with chemotherapy or targeted agents for urothelial cancers
Annual Meeting GU 2016 Immune checkpoint inhibitors in co...
398 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab
Annual Meeting GU 2016 Clinical trials in bladder cancer ...
467 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer
Annual Meeting GU 2016 Adjuvant radiation v. chemo-RT v. ...
480 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer
Annual Meeting GU 2016 Phase II trial of gemcitabine + ci...
385 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer Annual Meeting GU 2016
Recommendations for the utilization of molecular factors ...
916 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Ongoing clinical trials that will establish a clinical role for molecular risk factors in prostate cancer
Ongoing clinical trials that will establish a clinical ro...
258 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Molecular markers that have been identified in prognosis and risk of relapse in localized prostate cancer.
Molecular markers that have been identified in prognosis ...
340 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Molecular markers have greater impact on risk of recurrence than cancer stage and PSA levels
Molecular markers have greater impact on risk of recurren...
257 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Genetic Testing in Prostate Cancer
Annual Meeting GU 2016 Genetic Testing in Prostate Cancer
479 Views
6 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Loading